Clinical evaluation of 5-fluorouracil from transdermal patches on EAC and DLA cell-induced tumors in mice

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 3, 2008, Pages 437-440

  Chandrashekar, N S ^a   Prasanth, V V ^b  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b Gautam College of Pharmacy   (India)

Author keywords

5 Fluorouracil; Cytotoxicity; Pharmacokinetics; Transdermal patch delivery

Indexed keywords

EID: 67650872969     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ansifield FJ, Schroeder JM, Curreri AR (1962). Five years clinical experience with 5-fluorouracil. J Am Med Assoc, 181, 295-99.
2. Bargman H, Hochman JJ (2003). Topical treatment of Bowen's disease with 5-fluorouracil. Cutan Med Surg, 7, 101-5.
3. Barberi-Heyob M, Merlin JL, Weber B (1992). Analysis of 5-fluorouracil in plasma and urine by high-performance liquid chromatography. J Chromatogr, 581, 281-6.
4. Chandrashekar NS, Shobharani RH (2008). Pressure sensitive adhesive for 6-mercaptopurine transdermal delivery for solid tumor in mice. J Macro Sci, Part A: Pure Applied Chem, 45, 93-9
5. Diasio RB, Harris BE (1989).Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinetics, 16, 215-37.
6. Epstein E (1985). Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol, 121, 207-13.
7. Flynn GL (1996). Cutaneous and transdermal delivery: Processes and systems of delivery. In: Banker GS, Rhodes CT, eds. Modern Pharmaceutics. New York, NY: Marcel Dekker:239-99.
8. Iigo M, Yamaizumi Z, Nishimura S, Hosh, A, Clerq E (1988). The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2bromovinyl)-2'-deoxyuridine. Jpn J Cancer Res, 78, 409-13.
9. Koenig H, Patel K (1970). Biochemical basis for fluorouracil neurotoxicity - the role of Krebs cycle inhibition by fluoroacetate. Arch Neurol, 23, 155-60.
10. Kubto T, Shimosato Y, Nagai K (1978). Experimental chemotherapy of carcinoma of the human stomach and colon serially transplanted in nude mice. Gann, 69, 299-309.
11. Masafumi H, Hiromu N, Keiko K, Iwao M, Yukihiko U (1992). Metabolism of Tegafur in rat liver -by in vivo 19F Magnetic resonance spectroscopy and chromatography. Jpn J Cancer Res, 83, 387-91.
12. McCarron PA, Woolfson AD, McCafferty DF, et al (1991). Cytotoxicity of 5-fluorouracil released from a bioadhesive patch into cervical tissue. Int J Pharm, 151, 69-74.
13. Robins P, Gupta AK (2002). The use of topical fluorouracil to treat actinic keratosis. Cutis, 70, 4-7.
14. Scheindlin S (2004). Transdermal drug delivery: Past, present, future. Molec Interventions, 4, 308-12.
15. Su MH, Lee LH, Addel GH, Earl KR, William HI (1994). An application of transdermal antiviral delivery systems to the establishment of a novel animal model approach in the efficacy evaluation for dermatological formulations. Drug Dev Ind Pharm, 20, 685-718.
16. Sheeja K, Shihab PK, Kuttan G (2004). Antitumor and immunomodulatoryactivity of Andrographis paniculata. Amala Res Bull, 24, 93-102.
17. Uchera N, Baba H, Nitta K, et al (1985).The therapeutic effects of orally administered 5'-deoxy-5-fluorouridine, 1-(2-tetahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors, Jpn J Cancer Res, 76, 1034-41.
18. Woolfson AD, McCafferty DF, McCarron PA, Price JH (1995). A bioadhesive patch cervical drug delivery system for administration of 5-fluorouracil tot cervical tissue. J Control. Release, 35, 676-81.